A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae
doi: https://doi.org/10.1101/2022.07.15.22277670
Hiroshi Yotsuyanagi
aThe Institute of Medical Science, The University of Tokyo, Tokyo, Japan
MD, PhDNorio Ohmagari
bDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
MD, PhDYohei Doi
cDivision of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
dDepartments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Japan
MD, PhDTakumi Imamura
eDrug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
MSTakuhiro Sonoyama
eDrug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
MD, PhDGenki Ichihashi
eDrug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
MPharmTakao Sanaki
fResearch Division, Shionogi & Co., Ltd., Osaka, Japan
PhDYuko Tsuge
eDrug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
MSTakeki Uehara
eDrug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
PhDHiroshi Mukae
gDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
MD, PhDData Availability
All data produced in the present study are available upon reasonable request to the authors
Posted January 12, 2023.
A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae
medRxiv 2022.07.15.22277670; doi: https://doi.org/10.1101/2022.07.15.22277670
A Phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)
Hiroshi Yotsuyanagi, Norio Ohmagari, Yohei Doi, Takumi Imamura, Takuhiro Sonoyama, Genki Ichihashi, Takao Sanaki, Yuko Tsuge, Takeki Uehara, Hiroshi Mukae
medRxiv 2022.07.15.22277670; doi: https://doi.org/10.1101/2022.07.15.22277670
Subject Area
Subject Areas
- Addiction Medicine (394)
- Allergy and Immunology (706)
- Anesthesia (197)
- Cardiovascular Medicine (2890)
- Dermatology (248)
- Emergency Medicine (433)
- Epidemiology (12635)
- Forensic Medicine (10)
- Gastroenterology (815)
- Genetic and Genomic Medicine (4498)
- Geriatric Medicine (411)
- Health Economics (719)
- Health Informatics (2877)
- Health Policy (1060)
- Hematology (381)
- HIV/AIDS (913)
- Medical Education (419)
- Medical Ethics (115)
- Nephrology (466)
- Neurology (4267)
- Nursing (228)
- Nutrition (626)
- Oncology (2237)
- Ophthalmology (637)
- Orthopedics (256)
- Otolaryngology (323)
- Pain Medicine (272)
- Palliative Medicine (83)
- Pathology (491)
- Pediatrics (1183)
- Primary Care Research (490)
- Public and Global Health (6846)
- Radiology and Imaging (1505)
- Respiratory Medicine (910)
- Rheumatology (431)
- Sports Medicine (378)
- Surgery (476)
- Toxicology (60)
- Transplantation (206)
- Urology (176)